Market Research Logo

Global Companion Diagnostics Market - Segmented by Treatment Type and Geography - Growth, Trends, and Forecasts (2018 - 2023)

Global Companion Diagnostics Market - Segmented by Treatment Type and Geography - Growth, Trends, and Forecasts (2018 - 2023)

The global companion diagnostics market has been estimated at USD 5.8 billion in 2017. The market is expected to register a CAGR of 22.7% during the forecast period (2018-2023). North America accounted for the largest market share, accounting for approximately 35% of the global market in 2017, while the Asia-Pacific region is estimated to register the fastest CAGR over the forecast period (2018-2023).

Personalized Medicines Accelerating Market Demand

One of the major factors driving the growth of the companion diagnostic market is the increasing demand for personalized medicines and awareness about the same among the population. Rising cases of adverse drug reactions related to drugs, due to the lack of efficacy, drive the need for companion diagnostics. With companies increasing their collaborations for better biomarkers and diagnostics to focus on cost regulations, there have been significant number of opportunities of its applications in indications other than cancer, like cardiovascular, neurological, etc. The high rise in capital is the basis for the prosperous future of this market .

High Cost of Development of Therapeutics– A Major Hurdle

One of the major hurdles restraining the market includes high cost involved in the development of therapeutics and diagnostic tests. With the high risk of failure in clinical trials, many companies prefer collaborations, in order to minimize their failure rate. But co-development is also expected to be highly expensive. So, for many individual manufacturers, the market seems to involve high-risk investment. Apart from this, several diagnostic companies feel uncertain over eventual agreement on the reimbursement status. All these factors restrict the market’s growth globally.

North America Dominates the Market

The global market for companion diagnostics is segmented on the basis of technology type, indication, and geographical regions. By geography, the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.

North America accounted for the largest market share, accounting for approximately 35% of the global market in 2017. The efficacy of several drugs range between 30-75%, and there have been rising cases of side effects related to therapeutics, such as Vioxx and Avandia, which has prompted people to look for alternatives and raised their awareness regarding the benefits of personalized medicine. These factors are driving the North American market. Apart from this, the Asia-Pacific region was estimated to register the fastest CAGR over the forecast period.

Recent Key Developments in the Market

  • January 2018: Myriad Genetics received FDA approval for BRACAnalysis CDx as Companion Diagnostic for Lynparza (olaparib).
  • January 2018: A new companion diagnostics agreement between Biocartis Group and Amgen was signed for the development of Idylla™ CDx biomarker tests, used in the treatment of certain solid tumors.
  • December 2017: HTG Molecular Diagnostics signed master collaboration with Merck KGaA, complementing the companion diagnostics agreement for biomarker research program.
Major Key players: ABBOTT LABORATORIES, DAKO (AGILENT TECHNOLOGIES), ROCHE HOLDINGS, QIAGEN NV, SEIMENS HELTHINEERS, TAKEDA PHARMACEUTICALS, MYRIAD GENETICS, THERMO FISHER SCIENTIFIC, TACOGEN, AND ILLUMINA INC., among others

Reasons to Purchase the Report

To know more about:
  • Current and future market outlook for companion diagnostics in developed and emerging markets
  • Analyzing various perspectives on the market with the help of Porter’s five forces analysis
  • The treatment type that is expected to dominate the market
  • The regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • Three-month analyst support, along with the Market Estimate sheet in Excel.
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.


1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Drivers
6.1.1 Companies Promoting Personalized Medicine and Targeted Therapy as a New Treatment Option
6.1.2 Increasing Cases of Adverse Drug Reactions
6.1.3 Co-Development of Drug and Diagnostic Technology
6.2 Restraints
6.2.1 High Cost Of Drug Development and Associated Clinical Trials
6.2.2 Reimbursement Issues among Many Countries
7. Market Segmentation
7.1 By Technology
7.1.1 Immunohistochemistry (IHC)
7.1.2 Polymerase Chain Reaction (PCR)
7.1.3 In Situ Hybridization (ISH)
7.1.4 Real-Time PCR (RT-PCR)
7.1.5 Gene Sequencing
7.1.6 Others
7.2 By Indication
7.2.1 Lung Cancer
7.2.2 Breast Cancer
7.2.3 Colorectal Cancer
7.2.4 Leukemia
7.2.5 Melanoma
7.2.6 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisitions Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Abbott Laboratories
9.2 Dako (Agilent Technologies)
9.3 Roche Holdings
9.4 Qiagen NV
9.5 Seimens Helthineers
9.6 Takeda Pharmaceuticals
9.7 Myriad Genetics
9.8 Thermo Fisher Scientific
9.9 Tacogen
9.10 Illumina Inc.
9.11 Others
10. Future of the Market
1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Drivers
6.1.1 Companies Promoting Personalized Medicine and Targeted Therapy as a New Treatment Option
6.1.2 Increasing Cases of Adverse Drug Reactions
6.1.3 Co-Development of Drug and Diagnostic Technology
6.2 Restraints
6.2.1 High Cost Of Drug Development and Associated Clinical Trials
6.2.2 Reimbursement Issues among Many Countries
7. Market Segmentation
7.1 By Technology
7.1.1 Immunohistochemistry (IHC)
7.1.2 Polymerase Chain Reaction (PCR)
7.1.3 In Situ Hybridization (ISH)
7.1.4 Real-Time PCR (RT-PCR)
7.1.5 Gene Sequencing
7.1.6 Others
7.2 By Indication
7.2.1 Lung Cancer
7.2.2 Breast Cancer
7.2.3 Colorectal Cancer
7.2.4 Leukemia
7.2.5 Melanoma
7.2.6 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisitions Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Abbott Laboratories
9.2 Dako (Agilent Technologies)
9.3 Roche Holdings
9.4 Qiagen NV
9.5 Seimens Helthineers
9.6 Takeda Pharmaceuticals
9.7 Myriad Genetics
9.8 Thermo Fisher Scientific
9.9 Tacogen
9.10 Illumina Inc.
9.11 Others
10. Future of the Market
1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Drivers
6.1.1 Companies Promoting Personalized Medicine and Targeted Therapy as a New Treatment Option
6.1.2 Increasing Cases of Adverse Drug Reactions
6.1.3 Co-Development of Drug and Diagnostic Technology
6.2 Restraints
6.2.1 High Cost Of Drug Development and Associated Clinical Trials
6.2.2 Reimbursement Issues among Many Countries
7. Market Segmentation
7.1 By Technology
7.1.1 Immunohistochemistry (IHC)
7.1.2 Polymerase Chain Reaction (PCR)
7.1.3 In Situ Hybridization (ISH)
7.1.4 Real-Time PCR (RT-PCR)
7.1.5 Gene Sequencing
7.1.6 Others
7.2 By Indication
7.2.1 Lung Cancer
7.2.2 Breast Cancer
7.2.3 Colorectal Cancer
7.2.4 Leukemia
7.2.5 Melanoma
7.2.6 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisitions Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Abbott Laboratories
9.2 Dako (Agilent Technologies)
9.3 Roche Holdings
9.4 Qiagen NV
9.5 Seimens Helthineers
9.6 Takeda Pharmaceuticals
9.7 Myriad Genetics
9.8 Thermo Fisher Scientific
9.9 Tacogen
9.10 Illumina Inc.
9.11 Others
10. Future of the Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report